



UT Cancer Institute
**CLINICAL TRIALS
NEWS**

Vol. 2 No. 2
Apr. 2006

a bi-monthly newsletter provided by the Clinical Trials Department at the UT Cancer Institute

The Benefits of Clinical Trials at UICI

Clinical trials offer access to the latest treatments, providing state-of-the-art quality care.

We learn about the newest treatments before they come to market. We gain experience with

the therapy and what to expect. They also provide a competitive edge for marketing, increasing referrals, and attracting patients.

REMINDER

National Cancer Survivor's Day

June 4th



Clinical Trials - Keys to Success!

Support and involvement: All staff understand that clinical trials are important. We need everyone's support!

Willingness to invest: It takes time, staff, training, and equipment to run a clinical trials program. We are in this for the long haul!

Good communication: Patients must feel they are getting top-notch care from a staff that is well-coordinated and systematic. We are all on the same page!

Metastatic Breast Cancer Patients are "Underserved"



San Antonio Breast Cancer Symposium


A survey of 697 women found that those living with advanced breast cancer often wanted more information, but many times could not find it or were unaware that information exists. (Living Beyond Breast Cancer.. lbcc.org) This underscores the need for long-term follow-up care and education for our patients!

Cancer ART Competition

The National Coalition for Cancer Survivorship & Eli Lilly

Who? You! (patients, families, healthcare providers, etc.)
When? Contest entries accepted now through July 31st
What? Oil, watercolor, acrylic, pastel, photography, etc.
Where? To receive more information, contact Anita Chernenwski at 800.734.4131 or email at achernewski@cprworldwideusa.com

Spread the word!



10 Highlights from ASH

- 1) Two new drugs, Dasatinib & AMN107 can overcome Gleevec resistance
- 2) Front-line monoclonal antibodies improve outcomes for adv. follicular lymphoma
- 3) Elderly patients with hematologic cancers respond well to radioimmunotherapy
- 4) Alemtuzumab prolongs survival in heavily pretreated CLL patients
- 5) New drug, Plerixafor, helps pateints collect sufficient stem cells for transplant
- 6) Maintenance rituximab extends lymphoma patient survival
- 7) Lenalidomide + dexamethasone prolong survival in previously treated myeloma
- 8) Steroid-resistant GvHD responds to novel treatments
- 9) AMG531 shows good activity in boosting platelet production
- 10) Cloned idiotype vaccine, idKLH, moves to Phase III Trials in NHL

the American Society of Hematology Annual 42nd Meeting

FDA FYIs

Approvals:

Revlimid (lenalidomide) - anemia
Femara (letrozole) - breast cancer
Nexavar (sorafenib tosylate) - kidney
Em end (aprepitant) - nausea



QUOTE Be the best that you can be today, and keep hope for a better tomorrow...a cancer survivor

Chemotherapy given directly to the liver improves survival for patients with colorectal cancer that has spread to the liver

Results from CALGB 9481 show that patients whose colorectal cancer has spread to the liver who received an approach called hepatic arterial infusion (HAI) – the administration of chemotherapy directly to the liver through a pump in the abdomen – fare better than those who received traditional, intravenous chemotherapy. Researchers found that the patients on the HAI therapy lived longer and had better quality of life than those receiving systemic therapy. *JCO Feb. 27, 2006*

Featured Protocol(s)

UTMC: A Phase I Study of CyberKnife Monotherapy for Localized Prostate Cancer *PI: Dan Green, M.D.*

Taiho Pharma: An Open Label, Non-Randomized, Multicenter, Two-Stage, Phase II Study of S-1 as 2nd Line Therapy for Patients with Metastatic Pancreatic Cancer. *PI: Wahid Hanna, M.D.*

Questions? Call Barbara Munsey in the Clinical Trials Office at (865) 544-9773